The number of shares and votes in BICO Group AB (publ) have increased as a result of an in-kind issue of 1,200,000 shares of series B which was carried out as part of the financing for the acquisition of Biosero, Inc. The Board of Directors resolved on the in-kind issue on December 28, 2021 pursuant to the authorization granted by the annual general meeting held on April 26, 2021 and the extraordinary general meeting held on November 17, 2021.
As of January 31, 2022, the total number of registered and outstanding shares in BICO Group AB (publ) amounts to 63,330,269, whereof 1,500,000 are shares of series A, together carrying in total 15,000,000 votes, and 61,830,269 are shares of series B, together carrying in total 61,830,269 votes. The share capital amounts to SEK 1,583,256.725. The company does not hold any treasury shares.
For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
This is information that BICO Group AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, on January 31, 2022, at 15:15 (CET).
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com